Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 76.5% | 70.4% | 407.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 35% | 61% | 69.9% | 68.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -124.2% | -230.5% | -328% | -1,692.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -138.4% | -268.9% | -368.7% | -1,840.7% |
| EPS Diluted | -3.83 | -4.9 | -4.25 | -4.86 |
| % Growth | 21.8% | -15.3% | 12.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |